Lyell Immunopharma Announces FDA Clearance of IND for LYL132, a T-cell Receptor Therapy for Solid Tumors Being Developed in Collaboration with GSK

Lyell Immunopharma, Inc. announced that US FDA has cleared an Investigational New Drug (IND) application to initiate a Phase I clinical trial for LYL132, an investigational T-cell receptor therapy for patients with solid tumors expressing New York esophageal squamous cell carcinoma 1 that the company is developing in collaboration with GSK.
[Lyell Immunopharma, Inc. (Globenewswire, Inc.)]
[zotpress userid=” items=’AAAAAAAA’ style=’apa’ cite=’yes’]
Press Release
Bookmark

No account yet? Register

Share

Lyell Immunopharma Announces FDA Clearance of IND for LYL132, a T-cell Receptor Therapy for Solid Tumors Being Developed in Collaboration with GSK

Lyell Immunopharma, Inc. announced that the US FDA has cleared an Investigational New Drug (IND) application to initiate a Phase I clinical trial for LYL132, an investigational T-cell receptor therapy for patients with solid tumors expressing New York esophageal squamous cell carcinoma 1 that the company is developing in collaboration with GSK.
[Lyell Immunopharma, Inc.]
[zotpress userid=’7992332′ items=’BBBBBBBB’ style=’apa’ cite=’yes’]
Press Release
Bookmark

No account yet? Register

Share

Constructing a Novel Signature Based on Immune-Related lncRNA to Improve Prognosis Prediction of Cervical Squamous Cell Carcinoma Patients

Researchers assessed the correlation between immune infiltration status, chemotherapeutics sensitivity, immune checkpoint proteins, and the signature.
[Reproductive Sciences]
[zotpress userid=” items=’AAAAAAAA’ style=’apa’ cite=’yes’]
Abstract
Bookmark

No account yet? Register

Share

Identifying Candidates for Immunotherapy with Cemiplimab to Treat Advanced Cutaneous Squamous Cell Carcinoma: An Expert Opinion

A multi-disciplinary advisory group of Italian cutaneous squamous cell carcinoma (CSCC) experts was convened to develop criteria to assist in identifying appropriate candidates for cemiplimab therapy in advanced CSCC, based on the literature and clinical experience.
[Therapeutic Advances in Medical Oncology]
[zotpress userid=” items=’AAAAAAAA’ style=’apa’ cite=’yes’]
Full Article
Bookmark

No account yet? Register

Share

Rubius Therapeutics Announces Dosing of First Patient in Phase I/II Trial of RTX-224, a Broad Immune Agonist, for the Treatment of Certain Solid Tumors

Rubius Therapeutics, Inc. announced that the first patient has been dosed in its Phase I/II clinical trial of RTX-224 for the treatment of patients with certain relapsed/refractory or locally advanced solid tumors, including non-small cell lung cancer, cutaneous melanoma, head and neck squamous cell carcinoma, urothelia carcinoma and triple-negative breast cancer.
[Rubius Therapeutics, Inc.]
[zotpress userid=” items=’AAAAAAAA’ style=’apa’ cite=’yes’]
Press Release
Bookmark

No account yet? Register

Share

Current Methods and Caveats to Risk Factor Assessment in Cutaneous Squamous Cell Carcinoma (cSCC): A Narrative Review

Investigators summarize the current cSCC literature with a focus on how differing clinical assessments within each of the five selected risk factors (perineural invasion, differentiation, depth of invasion, size, and location) can influence the evaluation of patient outcomes.
[Dermatology and Therapy]
[zotpress userid=” items=’AAAAAAAA’ style=’apa’ cite=’yes’]
Full Article
Bookmark

No account yet? Register

Share

The Potential Role of miR-1290 in Cancer Progression, Diagnosis, Prognosis, and Treatment: An oncomiR or Onco-Suppressor microRNA?

MiR-1290 was discovered for the first time in human embryonic stem cells, and under typical physiological situations, plays an essential role in neuronal differentiation and neural stem cell proliferation.
[Journal of Cellular Biochemistry]
[zotpress userid=” items=’SPXSDFJC’ style=’apa’ cite=’yes’]
Abstract
Bookmark

No account yet? Register

Share

Zinc-Finger Protein 750 Mitigates Malignant Biological Behavior of Oral CSC-Like Cells Enriched from Parental CAL-27 Cells

Scientists elucidated the role of ZNF750 in the inhibition of the renewal ability of CSCs derived from the oral squamous cell carcinoma cell line, CAL‑27.
[Oncology Let]
[zotpress userid=” items=’AAAAAAAA’ style=’apa’ cite=’yes’]
Full Article
Bookmark

No account yet? Register

Share

A Tumor-Derived Type III Collagen-Rich ECM Niche Regulates Tumor Cell Dormancy

Investigators studied how disseminated tumor cells sensed and remodeled the ECM to sustain dormancy.
[Nature Cancer]
[zotpress userid=” items=’EEEEEEEE’ style=’apa’ cite=’yes’]
Abstract
Bookmark

No account yet? Register

Share

SOTIO Announces Clinical Collaboration with MSD to Evaluate IL-15 Superagonist, SOT101, in Combination with KEYTRUDA® (Pembrolizumab) in Patients with Solid Tumors

SOTIO Biotech announced that it has entered into a clinical trial collaboration and supply agreement with MSD to evaluate the combination of SOT101, SOTIO’s IL-15 superagonist, and MSD’s KEYTRUDA® in patients with selected advanced/refractory solid tumors in the Phase II AURELIO-04 study.
[SOTIO Biotech]
[zotpress userid=’7992332′ items=’nan’ style=’apa’ cite=’yes’]
Press Release
Bookmark

No account yet? Register

Share

RNF168 Suppresses the Cancer Stem Cell-Like Traits of Nonsmall Cell Lung Cancer Cells by Mediating RhoC Ubiquitination

Researchers found that RNF168 expression was positively correlated with the overall survival, first-progression survival, and postprogression survival of lung adenocarcinoma, but not correlated with these survivals of squamous cell carcinoma of lung.
[Environmental Toxicology]
[zotpress userid=” items=’AAAAAAAA’ style=’apa’ cite=’yes’]
Abstract
Bookmark

No account yet? Register

Share
Share